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SUMMARY
In utero hematopoietic stem/progenitor cell transplantation (IUHSCT) has only been fully successful in the treatment of congenital immunodeficiency diseases. Using sheep as a large animal model of IUHSCT, we demonstrate that administration of CD146 + CXCL12
+ VEGFR2 + or CD146 + CXCL12 + VEGFR2 À cells prior to, or in combination with, hematopoietic stem/progenitor cells (HSC), results in robust CXCL12 production within the fetal marrow environment, and significantly increases the levels of hematopoietic engraftment. While in the fetal recipient, donor-derived HSC were found to reside within the trabecular bone, the increased expression of VEGFR2 in the microvasculature of CD146 + CXCL12 + VEGFR2 + transplanted animals enhanced levels of donor-derived hematopoietic cells in circulation. These studies provide important insights into IUHSCT biology, and demonstrate the feasibility of enhancing HSC engraftment to levels that would likely be therapeutic in many candidate diseases for IUHSCT.
INTRODUCTION
In utero hematopoietic stem cell transplantation (IUHSCT) is a clinically viable therapeutic option, which could potentially provide successful treatment for many genetic and developmental diseases affecting the immune and hematopoietic systems (MacKenzie et al., 2015) . IUHSCT has safely been performed for decades in humans and is the only approach that can promise the birth of a healthy infant (Muench and Barcena, 2004; Nijagal et al., 2012) . To date, its success has been limited to recipients with severe combined immunodeficiency disorders in which there is a selective advantage of donor cell engraftment/survival over host cells (Flake et al., 1996; Gotherstrom et al., 2014; Le Blanc et al., 2005; Touraine et al., 1989; Wengler et al., 1996) . Because IUHSCT must be performed without myeloablation or immunosuppression, immunologic barriers and absence of stress-induced signaling have been considered as significant contributors to the limited donor HSC engraftment (Merianos et al., 2009; Nijagal et al., 2011; Peranteau et al., 2007) . Other challenges observed with IUHSCT result from the unique intricacies of fetal hematopoietic stem/progenitor cell (HSC) biology and the fetal microenvironment. It has been postulated that transplanted adult cells could potentially be outcompeted by endogenous fetal HSC, since the latter are actively cycling and undergo symmetric self-renewal divisions more efficiently than adult HSC (Bowie et al., 2007) . Also, the fetal microenvironment might not be appropriate to support engraftment and/or expansion of donor HSC derived from ontogenically disparate sources, as differences in membrane composition and response to cytokines exist between fetal and adult cells (Arora et al., 2014; Bowie et al., 2007; Derderian et al., 2014) . MCAM/CD146, within the adult human bone marrow (BM), is a marker of stromal progenitors/pericytes (Sacchetti et al., 2007) , which produce stromal cell-derived factor 1 (SDF-1/CXCL12) and stem cell factor (SCF), and mediate HSC maintenance/retention (Corselli et al., 2013; Sugiyama et al., 2006) , while VEGFR2/Flk-1 was shown to specifically define a continuous network of arterioles and sinusoidal endothelial cells within the BM, which are essential for HSC engraftment and reconstitution of hematopoiesis (Butler et al., 2010; Hooper et al., 2009; Kiel et al., 2005) . Moreover, in an adult setting, CD146-expressing subendothelial cells have been shown, upon transplantation, to be able to transfer the hematopoietic microenvironment to heterotopic sites (Sacchetti et al., 2007) .
Here, we investigated whether transplantation of allogeneic adult BM-derived CD146-expressing mesenchymal (CD146 + CXCL12 + VEGFR2 À ) or endothelial (CD146 + CXCL12 + VEGFR2 + ) cells resulted in stable long-term contribution/integration into specific fetal BM niches, and whether administration of these cells, simultaneously with, or prior to, HSC transplantation, improved levels of HSC engraftment in an in utero setting. In addition, since information about the preferential engraftment sites of adult-derived HSC within the fetal microenvironment after IUHSCT is scarce, we also investigated whether and where donor-derived HSC localized in the fetal BM, and whether they underwent cell cycling. We also evaluated, in the (Sacchetti et al., 2007) , and continued to express CD146 ( Figure 1H ). Percentage of cells positive for the different specific markers was calculated after counting a total of 1,139 ± 207 DAPI + nuclei/experiment and determining, within these, the number of cells also positive for a specific marker (n = 3 animals per group, three independent experiments). Animals were randomly selected from the pool of transplanted animals with CD146 ++À cells (n = 11) or CD146 +++ cells (n = 7). DAPI (blue) labels all nuclei. Arrows indicate features enlarged in insets. Confocal images were acquired with an Olympus Fluoview FV1000 confocal microscope; for most of the images an Olympus UPlanFLN 403/1.30 oil objective was used; a Plan ApoN 603/1.42 objective was also used as noted. 603 magnification was used in (C). Confocal images were taken as z stacks with 5-10 slices per image before being projected as 2D images and saved. Detailed characterization of CD146 ++À and CD146 +++ cells is provided in Figure S1 . Figure 1 . Figure S2 .
(CFU) assays, performed using freshly collected BM, showed that 3 +++ animals contained a significantly (p < 0.05) higher number of donor-derived (GFP + ) CFU than the other transplant groups, attesting to the higher clonogenic potential of the engrafted cells in this group (Figure 4B ). Of note, concurrent transplantation of HSC and CD146 +++ cells (0 +++ ) did not significantly increase the clonogenic potential of the engrafted cells beyond that seen with HSC alone ( Figure 4B ). In the metaphysis of animals that received HSC 3 days after CD146
++À cell transplant (3 ++À ) and HSC simultaneously with CD146 ++À cells (0 ++À ), the percentage of donor-derived HSC engraftment was significantly higher (p < 0.05) than in the group transplanted with HSC alone (HSC) ( Figure 4C ). However, no statistical significance was found between the percentage of donor-derived hematopoietic engraftment and clonogenic potential of engrafted cells in animals that received 3 ++À and 0 ++À ( Figure 4D ).
Analysis of the diaphysis also demonstrated that, in all of the recipients ( Figures 5A and 5B +++ and HSC, n = 2 animals per group; each with n = 3 technical replicates). (C) HSC3 + CD146 ++À and HSC0 + CD146 ++À animals had significantly higher HSC engraftment (*p < 0.05) than the HSC group (n = 3 animals/group; three independent experiments). (D) CFU assays performed using freshly collected BM from transplanted animals showed that HSC3 + CD146 ++À animals contained a higher number of donor-derived (GFP + ) CFU than the other transplant groups, but statistical significance was not achieved (n = 3 animals/group; each with n = 3 technical replicates). levels of donor cells (p < 0.05) than those receiving HSC alone, 0 +++ , 3 ++À , or 0 ++À ( Figure 5D ).
Donor-Derived HSC Are Not Detected within the Fetal Liver of Transplanted Animals
We next performed studies to confirm that donor-derived hematopoiesis was mainly localized to the BM, and that the higher levels of donor hematopoietic cells in circulation seen with some of the transplanted groups were not due to establishment of donor-derived hematopoiesis within the liver of the fetal recipients. No donor (GFP + ) hematopoietic cells were detected in the liver of any of the transplanted animals, regardless of the transplantation scheme ( Figure 6A , left panel), despite the presence of host/recipient CD45 + cells within this tissue ( Figure 6A , right panel). Of note is that, after in utero transplantation, both donor-derived mKate + stromal cell populations were detected at significant levels within the hepatic parenchyma ( Figures 6B and 6C [central panels], and Figure 6D ). Elevation of SDF-1 levels in PB can mobilize HSC to the circulation, with a concomitant decrease of HSC within the BM (Hattori et al., 2003 Figure 1 . (C) Correlation between the numbers of donor-derived CD146 + cells (red) engrafted within the vasculature and the numbers of donorderived GFP + hematopoietic cells present in the perivascular areas (defined as being within a distance of five nuclei from vessel) (n = 7 animals). (D) Percentages of circulating donor hematopoietic cells in animals transplanted with different cell populations determined by flow cytometric analysis (*p < 0.05). n = 3 animals per group and two independent experiments, except for HSC3 + CD146 +++ and HSC groups (n = 2 animals per group with two independent experiments).
engrafted the liver continued to express this chemokine ( Figures 6B and 6C) . A graphical depiction of the relative contribution of donor-derived CD146 +++ and CD146 ++À cells to overall SDF-1 production within the recipient fetal liver is shown in Figure 6E .
DISCUSSION
Similarly to unconditioned adult recipients, transplantation of allogeneic HSC into non-ablated fetal hosts faces serious challenges. Immunologic barriers posed by the mother's immune system (Merianos et al., 2009; Nijagal et al., 2011) and by the emerging innate and adaptive immunity of the host (Bhattacharya et al., 2006; De Kleer et al., 2014; Peranteau et al., 2007; Rechavi et al., 2015; Renoux et al., 2015; Szepfalusi et al., 2000; Xu et al., 2004) can lead to graft rejection, or at least significant graft loss, before donor-specific tolerance is achieved (Peranteau et al., 2015) . For example, in non-irradiated adult animals, only continuous infusion (Wright et al., 2001) or transplantation of extraordinarily high doses of BM HSC (Rao et al., 1997) have resulted in hematopoietic chimerism; such approaches would be challenging to implement in a fetal setting. + nuclei/experiment and determining, within these, the number of cells also positive for the respective markers (n = 3 per group). DAPI (blue) labels all nuclei. Confocal images were acquired as described in Figure 3 .
Robust long-term engraftment of adult-derived cells in a fetal setting also depends upon the ability of adult cells to effectively compete with endogenous cells for the appropriate niches (Bhattacharya et al., 2006; Calvi et al., 2003; Ding et al., 2012; Greenbaum et al., 2013; Kunisaki et al., 2013) and the existence of fully functional microenvironments (Jeanblanc et al., 2014 ) that can support/promote adult hematopoiesis.
The fetal sheep model (Flake et al., 1986 ) has proved to be instrumental in developing strategies for IUHSCT, since it is outbred and therefore genetically diverse, and parallels human immune and hematopoietic development; moreover, data collected in this model were used by Flake et al. (1996) to design the transplantation approach to achieve the first clinical cure with IUHSCT. Nevertheless, like any other animal model, sheep cannot exactly reproduce all the features of human pregnancy. For instance, probably due to the type of placentation, ewes do not modulate maternal immunity toward a more tolerogenic phenotype, and therefore the role of maternal immunity in fetal transplant rejection cannot be addressed in this model (Entrican et al., 2015) .
Nevertheless, using this model, we demonstrated the possibility of increasing hematopoietic engraftment after IUHSCT by the administration of stromal elements (Almeida- Porada et al., 1999 Porada et al., , 2000 . However, we did not characterize which populations within the adult stromal cells were responsible for the effect, nor did we address the interaction between transplanted HSC and stromal cells or the long-term fate and localization of the transplanted cell populations, leaving unanswered the questions of whether and where within the BM these cells lodged.
In these studies, we show that CD146 ++À or CD146 +++ cells are responsible for the significant increase in the levels of donor-derived hematopoietic engraftment, and that CD146 ++À and CD146 +++ cells engrafted long-term, localized almost exclusively within the diaphysis of the fetal BM, and integrated within the bone and perivascular niches. By contrast, transplanted CD146 ++À and CD146 +++ cells did not reside within the metaphysis of fetal recipients. Unexpectedly, the vast majority of the transplanted HSC, independent of the transplantation schedule/approach, were found within the metaphysis, where they were actively cycling, demonstrating that adult cells can efficiently divide in the fetal microenvironment. Since our analysis was performed at over 2 months after IUHSCT, the results obtained reflect an examination of the localization of the transplanted HSC in the ''steady state,'' after durable engraftment took place. We also show that a direct correlation exists between the levels of donor-derived CD146 ++À or CD146 +++ cells within perivascular regions of the diaphysis and the levels of donor hematopoietic engraftment seen in the vicinity (within five cell nuclei) of vasculature containing donorderived niche cells. This finding could suggest that providing an adult-derived perivascular niche enables more donor-derived HSC to migrate to or engraft within the BM. During fetal development, long bones are the primary site for BM hematopoiesis (Proytcheva, 2013) and, given that blood flow through the long bones proceeds mostly from the diaphysis to the metaphysis, the engraftment of CD146 ++À CD146 +++ cells within the diaphysis and their production of hematopoiesis-supporting chemokines may serve to attract transplanted HSC to the marrow cavity, from whence they are then drawn to the metaphysis by the active bone remodeling at this stage of development and by the high hyaluronic acid synthase levels present in that region ( Figure S2 , top panel) when compared with the diaphysis of fetal sheep ( Figure S2 , lower panel). These data are in agreement with prior studies demonstrating that hyaluronan levels play a critical role in determining the site of HSC lodgment/engraftment following transplantation (Avigdor et al., 2004; Ellis et al., 2007 Ellis et al., , 2009 Ellis et al., , 2011 Nilsson et al., 2003) , and that HSC exhibit preferential engraftment within sites of active bone remodeling (Chan et al., 2009 ).
In the adult, SDF-1/CXCL12 plays a critical role in BM repopulation by circulating CD34 + progenitors (Peled et al., 1999a (Peled et al., , 1999b , and during development, SDF-1 induces the migration of primitive HSC from the fetal liver to the BM (Ma et al., 1998) and promotes HSC colonization (Ara et al., 2003) . Likewise, membrane-bound SCF is important for HSC maintenance (Barker, 1997) and myeloid development after transplantation (Takagi et al., 2012 (Domev et al., 2014; English et al., 2010; Le Blanc and Davies, 2015; Le Blanc et al., 2007) , perhaps protecting the transplanted HSC from the rudimentary immune elements present within the fetus at this stage of gestation (Skopal-Chase et al., 2009 (Hooper et al., 2009) , VEGFR2 seems to play a role in increasing hematopoietic engraftment in the fetal recipient. This could be due to VEGFR2's ability to promote survival of hematopoietic progenitors through the activation of anti-apoptotic pathways (Larrivee et al., 2003) and/or stimulating the formation of hematopoietic-supporting hemospheres . It is also of note that the data presented here corroborate reports demonstrating that mesenchymal stromal cells transplanted in utero contribute to the forming bone, and could therefore be of clinical benefit for patients with osteogenesis imperfecta (Gotherstrom et al., 2014) . More importantly, we demonstrate that a substantial fraction of transplanted stromal cells were found in the liver and never reached the BM, underscoring the need for defining strategies to increase bone engraftment of mesenchymal cells after in utero transplantation (Jones et al., 2012; Millard et al., 2015) .
Overall, these studies demonstrate that in a fetal setting, transplanted HSC locate primarily in the metaphysis, and that both CD146 ++À and CD146 +++ stromal cells contribute, long-term, to the different BM niches and influence hematopoiesis through CXCL12, crucial for successful HSC engraftment in a fetal setting. Moreover, we show the feasibility of using a co-transplantation strategy that significantly (>10-fold) enhances donor HSC engraftment following IUHSCT. Because stromal cells have been transplanted safely in fetal recipients, confirmation of these results in another preclinical model would allow this straightforward and clinically viable approach to be used in a clinical setting to achieve levels of hematopoietic cell engraftment that would likely be therapeutic in many of the diseases that are candidates for treatment by IUHSCT. from BMMNC by positive selection using anti-sheep CD34 (Genovac) and the MidiMACS system (Miltenyi Biotec) as previously described (Porada et al., 2008) .
EXPERIMENTAL PROCEDURES
Characterization of CD146 ++À or CD146 +++ Cells by
Immunocytochemistry and Tube-Formation Assay
To better characterize cell phenotype and functionality, we performed immunocytochemistry and tube-formation assays as detailed in Supplemental Experimental Procedures. For determination of whether CD146 ++À cells fulfilled the criteria of mesenchymal progenitors, these cells were induced to differentiate into adipocytes and osteocytes as previously described (Soland et al., 2012) and as detailed in Supplemental Experimental Procedures.
Lentiviral Vector Transduction
To facilitate tracking post-transplantation, we transduced CD146 +++ or CD146 ++À cells with the LVmKate-2 lentivector, and CD34 + HSCs with the Lv105-eGFP lentivector (both from Capital Biosciences), as detailed in Supplemental Experimental Procedures. CFU assays were performed to confirm preservation of hematopoietic engraftment capability (Wiley and Yeager, 1991) .
In Utero Transplantation and Tissue Collection
A total of 33 animals were used in these studies. Fetal sheep were injected intraperitoneally at 60-65 gestational days, which corresponds to $16-17 weeks of gestation in humans, by ultrasoundguided transabdominal percutaneous injection as described by Chamberlain et al. (2007) , and in accordance with IACUC guidelines, with different subsets of cells derived from the same donor:
(1) CD146 ++À and HSC simultaneously (n = 14); (2) CD146 ++À followed by HSC 3 days later (n = 4); (3) CD146 +++ and HSC simultaneously (n = 5); (4) CD146 +++ , followed by HSC 3 days later (n = 4); or (5) HSC alone (n = 4). CD146 ++À cells, CD146 +++ cells, and HSC were administered at a dose of 2.5 3 10 6 /kg, 7.1 3 10 6 /kg, and 2.1 3 10 6 /kg, respectively. Non-transplanted animals (n = 2) were used as controls.
Colony-Forming Cell Assays
BM aspirates were collected from the iliac crest at the time of euthanasia. Methylcellulose colony assays were performed by plating 10,000 BMMNC in MethoCult GF H4330 (StemCell Technologies) supplemented with PHA-stimulated sheep leukocyte-conditioned medium (PHA-LCM) (5% v/v), as previously described (Porada et al., 2008) . The percentage of GFP + colonies was calculated by dividing the number of GFP + colonies by the total number of GFP + and GFP À colonies.
Flow Cytometric Analysis
Flow cytometric analysis was performed to assess levels of donor hematopoietic cell engraftment. 
Immunohistochemistry
Long bones were collected, processed, and stained with antibodies to the lentivector-encoded reporter genes, cell-specific markers, and Ki67, as detailed in Supplemental Experimental Procedures, to examine the localization of the transplanted cells within the fetal sheep BM, levels of HSC engraftment, and proliferative status.
Statistical Analysis
All data are presented as mean ± SEM. We used GraphPad Prism 6 (GraphPad Software) for statistical analysis, and ordinary one-way ANOVA followed by a Holm-Sidak multiple comparisons test with a singled pooled variance. Spearman's correlation tests were applied to evaluate correlations. For all analyses, p % 0.05 was considered to be statistically significant. 
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